INZY Stock: Price, Forecast, Financials & AI Analysis

High

Open

VWAP

Vol

Mkt Cap

279.59M

Low

Amount

EV/EBITDA(TTM)

Total Shares

219.76M

EV/OCF(TTM)

P/S(TTM)

Inozyme Pharma, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing therapeutics that target the pyrophosphate (PPi)-Adenosine Pathway, a key regulator of bone health and blood vessel function. Its lead product candidate, INZ-701, is a soluble, recombinant, or genetically engineered, ENPP1 fusion protein that is designed to increase PPi and adenosine, to enable the potential treatment of multiple diseases caused by deficiencies in these molecules. The Company is conducting clinical trials of INZ-701 for the treatment of Ectonucleotide Pyrophosphatase/Phosphodiesterase 1 (ENPP1) Deficiency, ATP-Binding Cassette in the C6 family (ABCC6) Deficiency, and calciphylaxis. The Company also plans to investigate the potential of a next generation INZ-701 molecule to address posterior longitudinal ligament (OPLL).

Events Timeline

(ET)

2025-10-07

08:34:36

CervoMed Names Matthew Winton as Chief Commercial and Business Officer

2025-07-22 (ET)

2025-07-22

08:30:11

Sixteen option delistings on July 22nd

2025-05-16 (ET)

2025-05-16

13:26:28

Leerink bullish on BioMarin following Inozyme deal, expects additional BD

2025-05-16

09:29:29

BioMarin says Inozyme deal to strengthen enzyme therapies portfolio

2025-05-16

09:24:45

Inozyme downgraded to Neutral from Outperform at Wedbush

News

8.5

2025-07-01Newsfilter

BioMarin Announces Completion of Acquisition of Inozyme

7.0

2025-06-12PRnewswire

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates INZY, SVT, HLGN on Behalf of Shareholders

7.0

2025-05-27Globenewswire

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates INZY, TXNM, SVT, PTIX on Behalf of Shareholders

7.0

2025-05-27Globenewswire

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Inozyme Pharma, Inc. (Nasdaq – INZY), TXNM Energy, Inc. (NYSE - TXNM), Servotronics, Inc. (NYSE American - SVT), Protagenic Therapeutics, Inc. (Nasdaq – PTIX)

7.0

2025-05-22PRnewswire

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates AVDX, TASK, INZY on Behalf of Shareholders

7.0

2025-05-19PRnewswire

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates TXNM, SVT, INZY, PTIX on Behalf of Shareholders

8 Analyst Rating

Wall Street analysts forecast INZY stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for INZY is 7.50 USD with a low forecast of 4.00 USD and a high forecast of 16.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

2 Buy

6 Hold

0 Sell

Hold

Current: 0.000

Low

4.00

Averages

7.50

High

16.00

Current: 0.000

Low

4.00

Averages

7.50

High

16.00

Wells Fargo

Overweight

Equal Weight

downgrade

Al Analysis

2025-05-16

Reason

Wells Fargo

Price Target

Al Analysis

2025-05-16

downgrade

Overweight

Equal Weight

Reason

Wells Fargo downgraded Inozyme (INZY) to Equal Weight from Overweight with a $4 price target after BioMarin Pharmaceutical (BMRN) announced a definitive agreement to acquire the company for $4.00 per share in cash.

Needham

Joseph Stringer

Buy -> Hold

downgrade

2025-05-16

Reason

Needham

Joseph Stringer

Price Target

2025-05-16

downgrade

Buy -> Hold

Reason

Needham analyst Joseph Stringer downgraded Inozyme (INZY) to Hold from Buy without a price target after BioMarin Pharmaceutical (BMRN) announced a definitive agreement to acquire the company for $4.00 per share in cash.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for INZY

Unlock Now

Valuation Metrics

The current forward P/E ratio for Inozyme Pharma Inc (INZY.O) is -0.81, compared to its 5-year average forward P/E of -3.27. For a more detailed relative valuation and DCF analysis to assess Inozyme Pharma Inc 's fair value, Click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-3.27

Current PE

-0.81

Overvalued PE

-1.17

Undervalued PE

-5.38

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-1.47

Current EV/EBITDA

0.09

Overvalued EV/EBITDA

0.16

Undervalued EV/EBITDA

-3.09

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

0.00

Current PS

0.00

Overvalued PS

0.00

Undervalued PS

0.00

Financials

Al Analysis

Annual

Quarterly

Trading Trends

People Also Watch

Frequently Asked Questions

What is Inozyme Pharma Inc (INZY) stock price today?

The current price of INZY is 0 USD — it has increased 0 % in the last trading day.

What is Inozyme Pharma Inc (INZY)'s business?

What is the price predicton of INZY Stock?

Wall Street analysts forecast INZY stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for INZY is7.50 USD with a low forecast of 4.00 USD and a high forecast of 16.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is Inozyme Pharma Inc (INZY)'s revenue for the last quarter?

Inozyme Pharma Inc revenue for the last quarter amounts to -25.79M USD, increased 5.93 % YoY.

What is Inozyme Pharma Inc (INZY)'s earnings per share (EPS) for the last quarter?

Inozyme Pharma Inc. EPS for the last quarter amounts to -29151000.00 USD, increased 18.67 % YoY.

How many employees does Inozyme Pharma Inc (INZY). have?

Inozyme Pharma Inc (INZY) has 67 emplpoyees as of January 17 2026.

What is Inozyme Pharma Inc (INZY) market cap?

Today INZY has the market capitalization of 279.59M USD.

INZY Overview

INZY Overview

Events Timeline

News

Valuation Metrics

Forward PE

Forward EV/EBITDA

Forward PS

Financials

Trading Trends

People Also Watch

Frequently Asked Questions

What is Inozyme Pharma Inc (INZY) stock price today?

What is Inozyme Pharma Inc (INZY)'s business?

What is the price predicton of INZY Stock?

What is Inozyme Pharma Inc (INZY)'s revenue for the last quarter?

What is Inozyme Pharma Inc (INZY)'s earnings per share (EPS) for the last quarter?

How many employees does Inozyme Pharma Inc (INZY). have?

What is Inozyme Pharma Inc (INZY) market cap?